JP2021167309A - Fat reducer - Google Patents
Fat reducer Download PDFInfo
- Publication number
- JP2021167309A JP2021167309A JP2021074966A JP2021074966A JP2021167309A JP 2021167309 A JP2021167309 A JP 2021167309A JP 2021074966 A JP2021074966 A JP 2021074966A JP 2021074966 A JP2021074966 A JP 2021074966A JP 2021167309 A JP2021167309 A JP 2021167309A
- Authority
- JP
- Japan
- Prior art keywords
- fat
- blood
- reducing agent
- extract
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003638 chemical reducing agent Substances 0.000 title claims abstract description 37
- 239000008280 blood Substances 0.000 claims abstract description 38
- 210000004369 blood Anatomy 0.000 claims abstract description 38
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000000284 extract Substances 0.000 claims abstract description 31
- 239000009520 bofu-tsusho-san Substances 0.000 claims abstract description 20
- 230000001603 reducing effect Effects 0.000 claims abstract description 11
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 17
- 210000001268 chyle Anatomy 0.000 claims description 11
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 239000003925 fat Substances 0.000 description 15
- 239000000654 additive Substances 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 241000951473 Schizonepeta Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 241000544270 Angelica acutiloba Species 0.000 description 3
- -1 Sodium anhydride Chemical class 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000004534 Scutellaria baicalensis Species 0.000 description 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 2
- 241001575928 Siler Species 0.000 description 2
- 210000000579 abdominal fat Anatomy 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013583 drug formulation Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 241000212941 Glehnia Species 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- 235000016278 Mentha canadensis Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical class CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940124568 digestive agent Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940056729 sodium sulfate anhydrous Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
本発明は、脂肪低減剤に関する。より具体的には、本発明は、血中中性脂肪値が高い人に高い効果を示す脂肪低減剤に関する。 The present invention relates to a fat reducing agent. More specifically, the present invention relates to a fat-reducing agent that is highly effective in people with high triglyceride levels in blood.
血中中性脂肪は、血液中に存在するトリグリセライドであり、エネルギー源であるブドウ糖が不足した場合の代替エネルギー源として用いられる。血中中性脂肪の基準値は３０〜１４９ｍｇ／ｄＬとされている（非特許文献１）。 Neutral fat in blood is triglyceride present in blood and is used as an alternative energy source when glucose, which is an energy source, is deficient. The standard value of triglyceride in blood is 30 to 149 mg / dL (Non-Patent Document 1).
血中中性脂肪が基準値よりも高値になると、内臓脂肪の増加、血糖値の上昇、血圧の上昇等を引き起こす。血中中性脂肪が高くなる原因としては、糖尿病、腎疾患、内分泌疾患、肝疾患等の疾患、飲酒、食事内容、運動不足等の生活習慣、脂質が血中にたまりやすい体質、加齢等、多岐にわたる。 When the triglyceride level in the blood becomes higher than the standard value, it causes an increase in visceral fat, an increase in blood glucose level, an increase in blood pressure, and the like. Causes of high triglyceride in blood include diseases such as diabetes, renal disease, endocrine disease, liver disease, lifestyle-related diseases such as drinking, dietary content, lack of exercise, constitution in which lipids tend to accumulate in blood, aging, etc. , Wide variety.
血中中性脂肪が高値となると生じる身体状態の中でも、内臓脂肪の増加は腹周りの増加につながるため忌避心理がより一層強く働き、特に、肥満でない人にとってその傾向が強い。 Among the physical conditions that occur when the blood triglyceride level is high, the increase in visceral fat leads to an increase in the abdominal circumference, so that the repellent psychology works even more strongly, especially for non-obese people.
そこで、本発明は、血中中性脂肪が高値である対象に有用な脂肪低減剤を提供することを目的とする。 Therefore, an object of the present invention is to provide a fat-reducing agent useful for a subject having a high triglyceride level in blood.
本発明者らが鋭意検討を行ったところ、防風通聖散エキスに、血中中性脂肪が高値である対象に対して顕著に脂肪を低減する効果があることを見出した。本発明は、この知見に基づいて、更に検討を重ねることにより完成したものである。 As a result of diligent studies by the present inventors, it was found that Bofutsushosan extract has a remarkable effect of reducing fat in a subject having a high triglyceride level in blood. The present invention has been completed by further studies based on this finding.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． 防風通聖散エキスを含有し、血中中性脂肪が高値の対象に適用される、脂肪低減剤。
項２． 前記対象の血中中性脂肪値が１５０ｍｇ／ｄＬ以上である、項１に記載の脂肪低減剤。
項３． 前記対象が、乳びが認められる対象である、項１又は２に記載の脂肪低減剤。
項４． 前記対象が非肥満者である、項１〜３のいずれかに記載の脂肪低減剤。
項５． 前記対象が男性である、項１〜４のいずれかに記載の脂肪低減剤。
項６． 内臓脂肪を低減するために用いられる、項１〜５のいずれかに記載の脂肪低減剤。
That is, the present invention provides the inventions of the following aspects.
Item 1. A fat-reducing agent containing Bofutsushosan extract and applied to subjects with high triglyceride levels in blood.
Item 2. Item 2. The fat reducing agent according to Item 1, wherein the triglyceride level in the blood of the subject is 150 mg / dL or more.
Item 3. Item 2. The fat reducing agent according to Item 1 or 2, wherein the subject is a subject in which chyle is observed.
Item 4. Item 2. The fat reducing agent according to any one of Items 1 to 3, wherein the subject is a non-obese person.
Item 5. Item 2. The fat reducing agent according to any one of Items 1 to 4, wherein the subject is a male.
Item 6. Item 2. The fat reducing agent according to any one of Items 1 to 5, which is used for reducing visceral fat.
本発明によれば、血中中性脂肪が高値である対象に有用な脂肪低減剤が新たに提供される。 According to the present invention, a new fat reducing agent useful for a subject having a high triglyceride level in blood is provided.
本発明の脂肪低減剤は防風通聖散エキスを含有し、血中中性脂肪が高値である対象に適用されることを特徴とする。以下、本発明の脂肪低減剤について詳述する。 The fat-reducing agent of the present invention contains a bofutsushosan extract and is characterized by being applied to a subject having a high level of triglyceride in blood. Hereinafter, the fat reducing agent of the present invention will be described in detail.
有効成分
本発明の脂肪低減剤は、防風通聖散エキスを有効成分として含有する。防風通聖散を構成する生薬は、「一般用漢方処方の手引き」(厚生省薬務局監修、日薬連漢方専門委員会編集、薬業時報社発行)によれば、トウキ、シャクヤク、センキュウ、サンシシ、レンギョウ、ハッカ、ショウキョウ、ケイガイ、ボウフウ、マオウ、ダイオウ、ボウショウ、ビャクジュツ、キキョウ、オウゴン、カンゾウ、セッコウ、及びカッセキである。書簡によっては、前記生薬の内、ビャクジュツを含まないもの(例えば「経験漢方処方分量集」、大塚敬節・矢数道明監集、医道の日本社発行)や、オウゴンを含まないもの(例えば「続漢方あれこれ」大阪読売新聞社編、浪速社発行)がある。また、防風通聖散の処方によっては、ボウフウの代わりにハマボウフウを含むものや、ビャクジュツの代わりにソウジュツを含むものもある。本発明で用いることができる防風通聖散エキスは、これらのいずれの防風通聖散から得られるものであってもよいが、より一層高い脂肪低減剤を得る観点から、防風通聖散がビャクジュツ及びオウゴンを含む処方であることが好ましい。
Active ingredient The fat-reducing agent of the present invention contains bofutsushosan extract as an active ingredient. According to the "Guide for General Chinese Medicine Prescription" (supervised by the Ministry of Health and Welfare, edited by the Japan Yakuren Chinese Medicine Expert Committee, published by Yakuhin Jihosha), the crude drugs that make up Bofutsushosan are: Angelica acutiloba, peony, and licorice. Sanshishi, Forsythia, Hakka, Shokyo, Schizonepeta, Siler, Maou, Daiou, Bowsho, Byakujutsu, Kikyo, Ogon, Kanzo, Sekou, and Kaseki. Depending on the letter, some of the above-mentioned crude drugs do not contain Byakujutsu (for example, "Experienced Kampo Prescription Amount Collection", Keisetsu Otsuka / Domei Yakazu, published by Japan Co., Ltd.), and those that do not contain Scutellaria baicalensis (for example, "" There is a series of Chinese medicines, edited by Osaka Yomiuri Shimbun, published by Naniwasha). In addition, depending on the prescription of Bofutsushosan, some contain Hamaboufu instead of Bowfu, and some contain Sojutsu instead of Byakujutsu. The bofutsushosan extract that can be used in the present invention may be obtained from any of these bofutsushosan, but from the viewpoint of obtaining a higher fat reducing agent, bofutsushosan is used. And a formulation containing Scutellaria baicalensis is preferable.
防風通聖散を構成する各生薬の分量は、「一般用漢方処方の手引き」（厚生省薬務局監修、日薬連漢方専門委員会編集、薬業時報社発行）、「第十七改正日本薬局方」等によれば、トウキ１．２重量部、シャクヤク１．２重量部、センキュウ１．２重量部、サンシシ１．２重量部、レンギョウ１．２重量部、ハッカ１．２重量部、ショウキョウ０．３〜１．２重量部、ケイガイ１．２重量部、ボウフウ１．２重量部又はハマボウフウ１．２重量部、マオウ１．２重量部、ダイオウ１．５重量部、ボウショウ（硫酸ナトリウム無水物換算量）０．６〜１．５重量部、ビャクジュツ２重量部、キキョウ２重量部、オウゴン２重量部、カンゾウ２重量部、セッコウ２〜３重量部、及びカッセキ３〜５重量部である。また、書簡によっては、前記分量中、１．２重量部を全て１．５重量部としているものもある（例えば「明解漢方処方」、西岡一夫、高橋真太郎共著、浪速社発行）。さらに、上記書簡に示されている各生薬の分量のうち、ショウキョウの分量を０．６〜１．５重量部としてもよい。 The amount of each crude drug that makes up Bofutsushosan is "Guide for General Chinese Medicine Prescription" (supervised by the Ministry of Health and Welfare, edited by the Japanese Pharmacopoeia Special Committee, published by Yakuhin Jihosha), "17th Amendment Japan According to the Japanese Pharmacopoeia, 1.2 parts by weight of Angelica acutiloba, 1.2 parts by weight of Shakuyaku, 1.2 parts by weight of Senkyu, 1.2 parts by weight of Sanshishi, 1.2 parts by weight of Schizonepeta, 1.2 parts by weight of schizonepeta, 0.3 to 1.2 parts by weight of Shokyo, 1.2 parts by weight of Schizonepeta, 1.2 parts by weight of Siler or 1.2 parts by weight of Glehnia, 1.2 parts by weight of Maou, 1.5 parts by weight of Daiou, Bowsho (sulfate) (Sodium anhydride equivalent) 0.6 to 1.5 parts by weight, 2 parts by weight of Byakujutsu, 2 parts by weight of Kikyo, 2 parts by weight of Angelica acutiloba, 2 parts by weight of Kanzo, 2 to 3 parts by weight of Sekko, and 3 to 5 parts by weight of Casseki Is. In addition, depending on the letter, 1.2 parts by weight are all 1.5 parts by weight in the above amount (for example, "Meikaku Chinese Medicine Prescription", co-authored by Kazuo Nishioka and Shintaro Takahashi, published by Naniwasha). Further, among the amounts of each crude drug shown in the above letter, the amount of ginger may be 0.6 to 1.5 parts by weight.
本発明で用いることができる防風通聖散エキスは、上記の生薬を混合した生薬調合物を公知の手法で抽出することによって得ることができる。例えば、生薬調合物に対して、約１０〜２０倍量の水を加え、８０〜１００℃程度で１〜３時間程度撹拌して抽出する方法が挙げられる。 The bofutsushosan extract that can be used in the present invention can be obtained by extracting a crude drug formulation containing the above crude drugs by a known method. For example, a method of adding about 10 to 20 times the amount of water to the crude drug preparation and stirring at about 80 to 100 ° C. for about 1 to 3 hours for extraction can be mentioned.
上記の生薬又は生薬調合物から抽出されたエキスの形態及び形状は特に制限されず、溶媒を含む液状又は粘稠形態（エキス液形態又は軟エキス形態）、及び乾燥形態（エキス末形態）のいずれであってもよい。これらの形態のエキスは、上記の抽出方法により得られた抽出液を、必要に応じて濃縮処理や乾燥処理に供することによって得ることができる。乾燥処理の具体的な方法としては、スプレードライ、減圧濃縮乾燥、凍結乾燥等が挙げられる。また、乾燥処理(特に、スプレードライによる乾燥処理)に供する際には、必要に応じて、抽出液にデキストリン等の賦形剤を添加してもよい。 The form and shape of the extract extracted from the above crude drug or crude drug formulation are not particularly limited, and may be either a liquid or viscous form containing a solvent (extract form or soft extract form) or a dry form (extract powder form). It may be. The extracts in these forms can be obtained by subjecting the extract obtained by the above extraction method to a concentration treatment or a drying treatment, if necessary. Specific methods of the drying treatment include spray drying, vacuum concentration drying, freeze drying and the like. Further, when subjected to a drying treatment (particularly, a drying treatment by spray drying), an excipient such as dextrin may be added to the extract, if necessary.
その他の成分
本発明の脂肪低減剤は、有効成分である上記の生薬エキスのみからなるものであってもよいし、製剤形態に応じた添加剤や基剤を含んでいてもよい。このような添加剤及び基剤としては、薬学的に許容されることを限度として特に制限されないが、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、等張化剤、可塑剤、分散剤、乳化剤、溶解補助剤、湿潤化剤、安定化剤、懸濁化剤、粘着剤、コーティング剤、光沢化剤、水、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、界面活性剤、金属石鹸、低級アルコール類、多価アルコール、ｐＨ調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、矯味剤、香料、粉体、増粘剤、色素、キレート剤等が挙げられる。これらの添加剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。また、これらの添加剤及び基剤の含有量については、使用する添加剤及び基剤の種類、脂肪低減剤の製剤形態等に応じて適宜設定される。
Other Ingredients The fat-reducing agent of the present invention may consist only of the above-mentioned crude drug extract as an active ingredient, or may contain additives and bases depending on the formulation form. Such additives and bases are not particularly limited as long as they are pharmaceutically acceptable, but for example, excipients, binders, disintegrants, lubricants, tonicity agents, plasticizers, etc. Dispersants, emulsifiers, solubilizers, wetting agents, stabilizers, suspending agents, pressure-sensitive agents, coating agents, brighteners, water, fats and oils, waxes, hydrocarbons, fatty acids, higher alcohols , Esters, water-soluble polymers, surfactants, metal soaps, lower alcohols, polyhydric alcohols, pH adjusters, buffers, antioxidants, UV inhibitors, preservatives, flavoring agents, fragrances, powders, Examples include thickeners, pigments, chelating agents and the like. These additives may be used alone or in combination of two or more. The contents of these additives and bases are appropriately set according to the types of additives and bases to be used, the form of the fat-reducing agent, and the like.
また、本発明の脂肪低減剤は、有効成分である上記の漢方エキスの他に、必要に応じて、他の栄養成分や薬理成分を含有していてもよい。このような栄養成分や薬理成分としては、薬学的に許容されることを限度として特に制限されないが、例えば、制酸剤、健胃剤、消化剤、整腸剤、鎮痙剤、粘膜修復剤、抗炎症剤、収れん剤、鎮吐剤、鎮咳剤、去痰剤、消炎酵素剤、鎮静催眠剤、抗ヒスタミン剤、カフェイン類、強心利尿剤、抗菌剤、血管収縮剤、血管拡張剤、局所麻酔剤、生薬エキス、ビタミン類、メントール類等が挙げられる。これらの栄養成分や薬理成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。また、これらの成分の含有量については、使用する成分の種類等に応じて適宜設定される。 In addition to the above-mentioned Chinese herbal extract, which is an active ingredient, the fat-reducing agent of the present invention may contain other nutritional components and pharmacological components, if necessary. Such nutritional components and pharmacological components are not particularly limited as long as they are pharmaceutically acceptable, but for example, antacids, stomachic agents, digestive agents, intestinal regulators, antispasmodics, mucosal repair agents, anti-inflammatory agents, and astringents. Agents, antiemetics, antitussives, sputum, anti-inflammatory enzyme agents, sedative hypnotics, antihistamines, caffeines, cardiotonic diuretics, antibacterial agents, vasoconstrictors, vasodilators, local anesthetics, crude drug extracts, vitamins, menthol Kind and the like. These nutritional components and pharmacological components may be used alone or in combination of two or more. Further, the content of these components is appropriately set according to the type of the component to be used and the like.
製剤形態
本発明の脂肪低減剤の製剤形態については、経口投与が可能であることを限度として特に制限されないが、例えば、散剤、細粒剤、顆粒剤(ドライシロップを含む)、錠剤、丸剤、カプセル剤(軟カプセル剤、硬カプセル剤)等の固形状製剤;ゼリー剤等の半固形状製剤;液剤、懸濁剤、シロップ剤等の液状製剤が挙げられる。本発明の脂肪低減剤をこれらの製剤形態に調製するには、有効成分である上記の漢方エキス、並びに必要に応じて添加される添加剤、基剤、及び／又は薬理成分を用いて、通常の製剤化手法に従って製剤化すればよい。
Formulation form The formulation form of the fat-reducing agent of the present invention is not particularly limited as long as it can be orally administered, and for example, powders, fine granules, granules (including dry syrup), tablets, pills, and the like. Solid preparations such as capsules (soft capsules, hard capsules); semi-solid preparations such as jelly; liquid preparations such as liquids, suspensions and syrups. In order to prepare the fat-reducing agent of the present invention in these pharmaceutical forms, it is usual to use the above-mentioned Chinese herbal extract as an active ingredient and additives, bases and / or pharmacological components added as needed. It may be formulated according to the formulation method of.
用途
本発明の脂肪低減剤は、血中中性脂肪が高値の対象に対して、脂肪を低減する目的で使用される。好ましくは、本発明の脂肪低減剤は、中性脂肪を低減する目的で使用することができる。
Uses The fat-reducing agent of the present invention is used for the purpose of reducing fat in a subject having a high triglyceride level in blood. Preferably, the fat-reducing agent of the present invention can be used for the purpose of reducing triglycerides.
本発明の脂肪低減剤の対象の血中中性脂肪値としては、通常１５０ｍｇ／ｄＬ以上であり、好ましい形態においては、１６０ｍｇ／ｄＬ以上、１７０ｍｇ／ｄＬ以上、１７５ｍｇ／ｄＬ以上、２００ｍｇ／ｄＬ以上、２５０ｍｇ／ｄＬ以上、又は３００ｍｇ／ｄＬ以上であってもよい。なお、血中中性脂肪値は、空腹時の血液における中性脂肪値をいう。 The blood triglyceride level of the target of the fat reducing agent of the present invention is usually 150 mg / dL or more, and in a preferable form, 160 mg / dL or more, 170 mg / dL or more, 175 mg / dL or more, 200 mg / dL or more. , 250 mg / dL or more, or 300 mg / dL or more. The triglyceride level in blood refers to the triglyceride level in fasting blood.
また、本発明の脂肪低減剤は、乳びが認められるほど血中中性脂肪が高い対象に対しても好ましく適用される。なお、乳びは、空腹時の血液において認められるものをいう。 In addition, the fat-reducing agent of the present invention is preferably applied to a subject whose blood triglyceride is so high that chyle is observed. Chyle refers to what is found in fasting blood.
本発明の脂肪低減剤は、脂肪低減効果をより一層高める観点から、好ましくは非肥満者（具体的には、ＢＭＩが２５未満である人）に適用される。また、本発明の脂肪低減剤は、脂肪低減効果をより一層高める観点から、好ましくは男性に適用される。本発明の脂肪低減剤は、脂肪低減効果を各段に高める観点から、最も好ましくは非肥満の男性に適用される。 The fat-reducing agent of the present invention is preferably applied to non-obese persons (specifically, persons having a BMI of less than 25) from the viewpoint of further enhancing the fat-reducing effect. In addition, the fat-reducing agent of the present invention is preferably applied to men from the viewpoint of further enhancing the fat-reducing effect. The fat-reducing agent of the present invention is most preferably applied to non-obese men from the viewpoint of further enhancing the fat-reducing effect.
用量・用法
本発明の脂肪低減剤は経口投与によって使用される。本発明の脂肪低減剤の用量については、有効成分の種類、投与対象者の年齢、性別、体質等に応じて適宜設定されるが、例えば、ヒト１人に対して１日当たり、脂肪低減剤の有効成分である防風通聖散エキスの量（但し、生薬由来成分の量を指す。例えば、スプレードライ等による乾燥処理で賦形剤を用いずに調製されたエキス末を用いる場合は、エキス末そのものの量を指し、スプレードライ等による乾燥処理で賦形剤等の添加物を添加した状態で調製されたエキス末を用いる場合は、エキス末から当該添加物を除いた量を指す。）で、例えば１〜１０ｇ程度、好ましくは３〜８ｇ程度、より好ましくは４〜６ｇ程度となる量で、１日１〜３回、好ましくは２又は３回の頻度で服用すればよい。服用タイミングについては、特に制限されず、食前、食後、又は食間のいずれであってもよいが、食前（食事の３０分前）又は食間（食後２時間後）が好ましい。
Dosage and Usage The fat-reducing agent of the present invention is used by oral administration. The dose of the fat-reducing agent of the present invention is appropriately set according to the type of the active ingredient, the age, sex, constitution, etc. of the administration subject. The amount of bofutsushosan extract, which is the active ingredient (however, it refers to the amount of crude drug-derived ingredients. For example, when using an extract powder prepared by spray-drying or the like without using an excipient, the extract powder is used. Refers to the amount of the extract itself, and when using an extract powder prepared with additives such as excipients added by drying treatment such as spray drying, it refers to the amount obtained by removing the additive from the extract powder). For example, the dose may be about 1 to 10 g, preferably about 3 to 8 g, more preferably about 4 to 6 g, and may be taken 1 to 3 times a day, preferably 2 or 3 times a day. The timing of administration is not particularly limited and may be before meals, after meals, or between meals, but it is preferably before meals (30 minutes before meals) or between meals (2 hours after meals).
以下、本発明を実施例により具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be specifically described with reference to Examples, but the present invention is not limited to these Examples.
防風通聖散エキスの調製
原料生薬として、トウキ１．２（重量部、以下同じ）、シャクヤク１．２、センキュウ１．２、サンシシ１．２、レンギョウ１．２、ハッカ１．２、ショウキョウ１．２、ケイガイ１．２、ボウフウ１．２、マオウ１．２、ダイオウ１．５、硫酸ナトリウム無水物１．５、ビャクジュツ２．０、キキョウ２．０、オウゴン２．０、カンゾウ２．０、セッコウ２．０及びカッセキ３．０の割合で用い、これらを刻んだ後、水１２倍重量を用いて約１００℃で３０分間抽出し、遠心分離して抽出液を得た。抽出液を減圧下で濃縮し、スプレードライヤーを用いて乾燥した。なお、スプレードライヤーによる乾燥は、抽出液を回転数１００００ｒｐｍのアトマイザーに落下させ、１５０℃の空気の熱風を供給することによって行った。
As crude drugs for preparing bofutsushosan extract , Touki 1.2 (part by weight, same below), Shakuyaku 1.2, Senkyu 1.2, Sanshishi 1.2, Renkyo 1.2, Hacka 1.2, Shokyo 1.2, Keigai 1.2, Bofu 1.2, Maou 1.2, Daiou 1.5, Sodium Sulfate Anhydrous 1.5, Byakujutsu 2.0, Kikyo 2.0, Ogon 2.0, Kanzo 2. The mixture was used at a ratio of 0, Seckou 2.0 and Casseki 3.0, and after chopping these, extraction was performed at about 100 ° C. for 30 minutes using 12 times the weight of water, and the mixture was centrifuged to obtain an extract. The extract was concentrated under reduced pressure and dried using a spray dryer. The drying with a spray dryer was performed by dropping the extract onto an atomizer having a rotation speed of 10000 rpm and supplying hot air with air at 150 ° C.
試験例１
３０歳〜４０歳代（男性１０名、女性１０名）を対象とし、防風通聖散エキス錠を、１日あたり、前記調製例で調整した防風通聖散エキスの生薬由来成分の量が５．０ｇとなるよう、１２週間、１日３回食前又は食間に１回５錠を服用させた。防風通聖散エキスの服用前及び服用後において、ＢＭＩ、血中中性脂肪量（空腹時）、及び腹部脂肪面積測定に基づく内臓脂肪量の測定を行い、服用前後における内臓脂肪量の減少量を算出した。結果を表１及び表２に示す。
Test Example 1
For people in their 30s to 40s (10 males and 10 females), the amount of bofutsushosan extract tablets adjusted in the above preparation example was 5 per day. For 12 weeks, 5 tablets were taken 3 times a day before or between meals so as to be 0.0 g. Before and after taking Bofutsushosan extract, measure the amount of visceral fat based on BMI, triglyceride volume in blood (on an empty stomach), and abdominal fat area measurement, and reduce the amount of visceral fat before and after taking. Was calculated. The results are shown in Tables 1 and 2.
表１及び表２から明らかな通り、内臓脂肪量減少量の平均が、血中中性脂肪値が低い人（比較例１〜１０）で−４．３６ｇであることに対し、血中中性脂肪値が高い人（実施例１〜１０）で−２６．５１ｇであることから、血中中性脂肪値が高い人において顕著な内臓脂肪減少効果が認められた。 As is clear from Tables 1 and 2, the average amount of decrease in triglyceride mass in blood is -4.36 g in people with low triglyceride level in blood (Comparative Examples 1 to 10), whereas it is neutral in blood. Since the weight was -26.51 g in those with a high fat level (Examples 1 to 10), a remarkable visceral fat reducing effect was observed in those with a high blood triglyceride level.
また、内臓脂肪量減少量の平均が、血中中性脂肪値が高く非肥満である人（実施例１〜４）で−２９．１２５ｇであることに対し、血中中性脂肪値が高く肥満である人（実施例５〜１０）で−２４．７６７ｇであることから、非肥満の人において一層優れた内臓脂肪減少効果が認められた。 In addition, the average amount of decrease in visceral fat mass is -29.125 g in persons who are non-obese with high triglyceride level in blood (Examples 1 to 4), whereas the triglyceride level in blood is high. Since the weight was -24.767 g in obese people (Examples 5 to 10), a more excellent visceral fat reducing effect was observed in non-obese people.
さらに、内臓脂肪量減少量の平均が、血中中性脂肪値が高い男性（実施例１，２，５，６，１０）で−３６．８２ｇ、血中中性脂肪値が高い女性（実施例３，４，７，８，９）で−１６．２ｇであることから、男性において一層優れた内臓脂肪減少効果が認められた。 Furthermore, the average amount of decrease in visceral fat mass was -36.82 g for men with high triglyceride levels in blood (Examples 1, 2, 5, 6, 10), and women with high triglyceride levels in blood (implementation). In Examples 3, 4, 7, 8, 9), the weight was -16.2 g, indicating that a more excellent visceral fat reducing effect was observed in men.
特に、内臓脂肪量減少量の平均が、血中中性脂肪値が高く非肥満である男性（実施例１，２）で−４１．６ｇ、血中中性脂肪値が高く非肥満である女性（実施例３，４）で−１６．６５ｇ、血中中性脂肪値が高く肥満である男性（実施例５，６，１０）で−３３．６３３ｇ、血中中性脂肪値が高く肥満である女性（実施例７，８，９）で−１５．９ｇであることから、非肥満である男性において格別顕著な内臓脂肪減少効果が認められた。 In particular, the average amount of decrease in visceral fat mass is -41.6 g for men who are non-obese with high triglyceride levels in blood (Examples 1 and 2), and women who are non-obese with high triglyceride levels in blood. (Examples 3 and 4) -16.65 g, males with high triglyceride level in blood and obesity (Examples 5, 6 and 10) -33.633 g, high triglyceride level in blood and obese Since the weight was -15.9 g in a certain woman (Examples 7, 8 and 9), a particularly remarkable effect of reducing visceral fat was observed in a non-obese man.
試験例２
マウス（Ｃ５７ＢＬ／６Ｊマウス、５週齢、雄）に高脂肪食（ＨＦＤ３２、日本クレア株式会社）を４週間自由摂食させて飼育し、乳び（空腹時）が認められなかった試験群（乳びなし群）と、乳びが認められた試験群（乳びあり群）と、コントロール群（乳びが認められなかったマウスと乳びが認められたとの両方を同数含む）と、に分けた。試験群には、前記の高脂肪食に防風通聖散エキスを２重量％となるように配合した飼料を１ヶ月間自由給餌した。コントロール群には、防風通聖散エキスを配合していない高脂肪食を１ヶ月間自由給餌した。１ヶ月の飼育後、腹部脂肪面積測定を行い、内臓脂肪量を算出した。さらに、コントロール群における内臓脂肪量の平均を１００％とし、各試験群の内臓脂肪量の平均の比率（％）を算出した。結果を表３に示す。
Test Example 2
A test group in which mice (C57BL / 6J mice, 5 weeks old, male) were fed a high-fat diet (HFD32, Japan Claire Co., Ltd.) for 4 weeks and chyle (fasting) was not observed. Chyle-free group), test group with chyle (chyle group), and control group (including the same number of mice without chyle and chyle). divided. The test group was free-fed for one month with a feed containing the above-mentioned high-fat diet containing Bofutsushosan extract in an amount of 2% by weight. The control group was free-fed for one month with a high-fat diet containing no bofutsushosan extract. After 1 month of breeding, the abdominal fat area was measured and the visceral fat mass was calculated. Further, the average of the visceral fat mass in the control group was set to 100%, and the ratio (%) of the average visceral fat mass in each test group was calculated. The results are shown in Table 3.
表３から明らかなとおり、乳びあり群では防風通聖散の服用による内臓脂肪量の減少効果が、乳びなし群に比べて顕著に優れていた。 As is clear from Table 3, in the group with chyle, the effect of reducing the amount of visceral fat by taking Bofutsushosan was significantly superior to that in the group without chyle.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074966A JP2021167309A (en) | 2021-04-27 | 2021-04-27 | Fat reducer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074966A JP2021167309A (en) | 2021-04-27 | 2021-04-27 | Fat reducer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021167309A true JP2021167309A (en) | 2021-10-21 |
Family
ID=78080070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074966A Pending JP2021167309A (en) | 2021-04-27 | 2021-04-27 | Fat reducer |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2021167309A (en) |
-
2021
- 2021-04-27 JP JP2021074966A patent/JP2021167309A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023100869A (en) | Method for improving mitophagy in subject | |
| JP2023100870A (en) | Method for improving mitophagy in subject | |
| JP2019513693A (en) | Composition for amelioration of female menopausal symptoms comprising mandala mochi extract | |
| JP2021167309A (en) | Fat reducer | |
| JP7554040B2 (en) | Muscle mass loss inhibitor | |
| JP7523895B2 (en) | Visceral fat cell decomposition agent | |
| JP7523894B2 (en) | Fat burning accelerator | |
| JP7554041B2 (en) | Limb Slimming Agent | |
| JP7535838B2 (en) | Lipid excretion promoter | |
| JP2022094421A (en) | Liver function improver | |
| JP7068803B2 (en) | Pharmaceutical composition for reducing blood lipids | |
| JP7133982B2 (en) | tablet composition | |
| JP2023054194A (en) | Bofu-tsusho-san extract | |
| JP2021119125A (en) | Appetite-regulating hormone secretion normalizing agent | |
| JP6938315B2 (en) | tablet | |
| JP2022000423A (en) | Fat in feces discharge promoter | |
| JP2023067056A (en) | Hypogastric fat reducer | |
| WO2020137687A1 (en) | Core body temperature improving agent | |
| JP2022011232A (en) | Agent for suppressing protein synthesis inhibition | |
| Vakte et al. | Formulation and Evaluation of Nutraceutical tablets | |
| JP2021104952A (en) | Fibrogenesis inhibitor | |
| JP2019199473A (en) | UCP1 expression promoter | |
| JP2021104955A (en) | Agent of improving muscle mass reduction | |
| JP2024005919A (en) | Bladder mucosa enhancer | |
| JP2024017078A (en) | Muscle water content improving agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231222 |